The Pittsburgh Scientific and Data Research Center for the COPE-AKI Consortium (Pitt-SDRC)

COPE-AKI 联盟匹兹堡科学与数据研究中心 (Pitt-SDRC)

• 批准号: 10296801
• 负责人: Kaleab Z Abebe
• 金额: $ 74万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-19 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10296801
• 关键词: Acute; Acute Renal Failure with Renal Papillary Necrosis; Address; Adverse event; Ambulatory Care; Biometry; Cardiovascular system; Caring; Cessation of life; Chronic Kidney Failure; Clinical Data; Clinical Trials; Clinical Trials Design; Collaborations; Conduct Clinical Trials; Consensus; Continuity of Patient Care; Data; Data Analyses; Data Collection; Data Coordinating Center; Development; Dialysis procedure; Education; End stage renal failure; Gills; Glucose; Goals; Health; Hospitalization; Hospitals; Impaired health; Incidence; Information Dissemination; Injury to Kidney; Intervention; Kidney; Kidney Diseases; Knowledge; Lead; Manuals; Measurement; Medical; Medication Management; Monitor; Morbidity - disease rate; Nurses; Online Systems; Outcomes and Health Services Research; Participant; Patient Outcomes Assessments; Patient-Focused Outcomes; Patients; Persons; Pharmacists; Pharmacology; Phase; Population; Procedures; Process; Protocols documentation; Randomized; Recording of previous events; Records; Recurrence; Renin-Angiotensin-Aldosterone System; Reporting; Research; Research Design; Risk; Risk Factors; Safety; Sodium; Symptoms; Syndrome; System; Technology; Testing; Time; United States National Institutes of Health; Universities; adverse outcome; cardiovascular risk factor; clinical center; clinically relevant; data dissemination; data management; data quality; design; disability; evidence base; experience; follow-up; health management; health related quality of life; high risk; hospital readmission; kidney dysfunction; multi-component intervention; multidisciplinary; operation; patient engagement; patient oriented; primary outcome; process optimization; programs; protocol development; readmission rates; satisfaction; success; telehealth; treatment as usual; virtual visit

ABSTRACT Acute kidney injury (AKI) and chronic kidney disease (CKD) are “interconnected” syndromes in which each influences the other. CKD is a risk factor for AKI and AKI contributes to the development or progression of CKD, end-stage renal disease (ESRD), cardiovascular symptoms, and death, not to mention recurrent AKI episodes and impaired health-related quality of life (HRQoL). Processes of care after AKI hospitalization have been found to be suboptimal, with lack of continuity of care, delayed follow-up and suboptimal medication management exacerbating the risks of adverse outcomes. In addition, optimal pharmacologic therapy, such as blockade of the renin-angiotensin-aldosterone system (RAAS) or sodium-glucose cotransporter type 2 (SGLT2), has not been defined. The Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Consortium will address these important gaps in knowledge of optimal management of patients surviving an episode of moderate (stage 2) or severe (stage 3) AKI. The goal of the COPE-AKI Consortium will be to develop and test interventions to optimize processes of care and identify key pharmacologic and non-pharmacologic interventions to reduce morbidity among these high-risk patients. The Center for Clinical Trials & Data Coordination (CCDC) at the University of Pittsburgh is well poised to serve as the Scientific and Data Research Center (SDRC) for the COPE-AKI Consortium. Our multidisciplinary investigative team has a history of collaboration, wealth of experience and expertise, including expertise in acute and chronic kidney disease, critical and translational care, medication management, design of clinical trials, telehealth, clinical and data coordination, project administration support, biostatistics, measurement of patient-reported outcomes, health services research and patient engagement. Our goal is to serve as the Scientific and Data Research Center for the COPE-AKI Consortium. Specifically, we will 1) establish an efficient and rigorous process for designing the Consortium study, including protocol development and adaptation of an existing web-based data collection system; 2) provide comprehensive expertise for data management and analysis within the Consortium; and 3) provide program coordination and administrative support throughout all phases of the study.

抽象的 急性肾脏损伤（AKI）和慢性肾脏病（CKD）是“相互联系的”综合症 每个人都会影响彼此。 CKD的发展或进展，末期肾脏疾病（ESRD），心血管症状， 和死亡，不要保持复发性AKI情节和与健康相关的生活质量受损 （HRQOL）。 缺乏护理连续性，随访延迟和次优药物管理 加剧不良结果的风险。 肾素 - 肌动蛋白 - 醛固酮系统（RAAS）或钠 - 葡萄糖共转运蛋白的封锁 2型（SGLT2）尚未定义。 （Cope-Aki）财团将解决最佳知识的重要差距 在中度（第2阶段）或严重（第3阶段）AKI中幸存的患者 Cope-Aki财团的目标将开发和测试干预措施以优化 护理过程并确定关键的药理学和非药物干预措施 这些高危患者的发病率。 匹兹堡大学的协调（CCDC）非常有索赔作为科学和 COPE-AKI联盟的数据研究中心（SDRC） 调查团队拥有合作的历史，丰富的经验和专业知识，包括 急性和慢性肾脏疾病，关键和转化护理，药物治疗方面的专业知识 管理，临床试验设计，远程医疗，临床和数据协调，项目 行政支持，生物统计学，对患者报告结果的测量，健康 服务研究和患者英语。 COPE-AKI联盟研究中心。 设计财团研究的严格过程，包括协议制定和 现有的基于Web的数据收集系统的改编； 2 在财团内进行数据管理和分析； 3）提供计划协调 和整个tudy阶段的行政支持。